EDWARDS LIFESCIENCES CORPORATION Funds and ETFs Edwards Lifesciences Corporation
Equities
EW
US28176E1082
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 87.46 USD | -3.05% |
|
-2.99% | +14.70% |
| May. 23 | Some of the biggest splits in Corporate America | RE |
| May. 22 | Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98 | MT |
ETFs positioned on Edwards Lifesciences Corporation
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 2.46% | 42 M€ | +2.04% | - | |
| 2.34% | 17 M€ | +8.31% | - | |
| 2.13% | 6 M€ | 0.00% | - | |
| 1.17% | 224 M€ | +4.30% | - | |
| 1.17% | 24 M€ | +0.63% | - | |
| 1.17% | 26 M€ | +0.88% | - | |
| 1.11% | 14 M€ | -3.15% | ||
| 1.06% | 2 M€ | 0.00% | ||
| 0.97% | 1 M€ | +2.21% | - | |
| 0.94% | 4,592 M€ | +11.18% | ||
| 0.89% | 37 M€ | -.--% | ||
| 0.73% | 9 M€ | -.--% | - | |
| 0.52% | 1 M€ | +16.32% | ||
| 0.46% | 2 M€ | +20.44% | - | |
| 0.44% | 5 M€ | -72.95% | - | |
| 0.42% | 3,859 M€ | +18.82% | - | |
| 0.42% | 469 M€ | -2.05% | ||
| 0.36% | 8 M€ | 0.00% | ||
| 0.36% | 2,383 M€ | +14.57% | ||
| 0.34% | 36 M€ | +22.19% | ||
| 0.33% | 50 M€ | +11.38% | ||
| 0.33% | 25 M€ | +4.49% | - | |
| 0.30% | 727 M€ | +9.15% | ||
| 0.30% | 219 M€ | +17.17% | - | |
| 0.30% | 1,448 M€ | -.--% | - | |
| 0.25% | 264 M€ | -.--% | - | |
| 0.24% | 187 M€ | +11.14% | - | |
| 0.24% | 477 M€ | +12.72% | ||
| 0.24% | 330 M€ | -.--% | ||
| 0.23% | 2 M€ | +14.69% | - | |
| 0.23% | 8 M€ | +7.53% | - | |
| 0.23% | 744 M€ | +10.58% | ||
| 0.21% | 276 M€ | +11.40% | - |
Edwards Lifesciences Corporation specializes in designing, manufacturing and marketing medical systems and devices for treating cardiovascular diseases. Net sales break down by family of products as follows:
- heart valves and surgery products (67.9%);
- hemodynamic monitoring systems (15.5%);
- other (16.6%): balloon catheters, artificial implants, etc.
Net sales are distributed geographically as follows: the United States (58.4%), Europe (22.2%), Japan (7.6%) and other (11.8%).
Calendar
2024-07-24
- Q2 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
90.21
USD
Average target price
96.16
USD
Spread / Average Target
+6.60%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.70% | 54.36B | |
| +10.22% | 226B | |
| +12.99% | 198B | |
| +18.09% | 142B | |
| +28.66% | 111B | |
| +2.09% | 65.26B | |
| +6.68% | 50.94B | |
| +8.29% | 44.8B | |
| +2.60% | 36.8B | |
| +23.00% | 32.07B |
- Stock Market
- Equities
- EW Stock
- Funds and ETFs Edwards Lifesciences Corporation
